Trial Profile
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms COSMOS
- Sponsors Janssen R&D Ireland
- 17 Apr 2016 Results assessing NS3 resistance-associated variants from COSMOS and OPTIMIST-1/-2 studies (n=53) presented at The International Liver Congress™ 2016
- 08 Apr 2015 Results will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL), as per Janssen Sciences media release.
- 28 Jul 2014 Results published in the Lancet.